Why classification comes before the submission strategy
The classification of medical equipment is a risk-based regulatory decision. It determines which controls, technical evidence, conformity assessment route and post-market duties apply before a product can be placed on a market. In regulatory language, “medical equipment” is usually treated as a type of medical device when it is intended for diagnosis, prevention, monitoring, treatment or support of a medical purpose. The same physical product may fall into a different class if its intended use, indications, patient population, software function or mode of contact changes. For more regulatory background, see the site’s Regulatory section.
Classification is not the same as a hospital asset category, customs code or marketing description. Regulators ask a narrower question: what risk does the product create for patients, users or public health, and what level of control is needed to provide reasonable assurance of safety and performance? This article summarizes official FDA materials, Regulation (EU) 2017/745, Regulation (EU) 2017/746, MDCG guidance and IMDRF principles current to October 2026.
How the FDA classifies medical devices
In the United States, the FDA uses three regulatory classes: Class I, Class II and Class III. FDA materials explain that device classification is based on the controls needed to provide reasonable assurance of safety and effectiveness. The FDA has established classifications for approximately 1,700 generic types of devices, grouped into 16 medical specialty panels. In practice, a manufacturer normally starts by identifying the relevant generic device type, classification regulation and product code in the FDA Product Classification Database.
Intended use and indications drive the class
The FDA does not classify equipment by hardware alone. Intended use and indications for use are central. A general-purpose imaging component, for example, may have a different regulatory profile from a diagnostic system intended to detect a specific disease state. Claims in labeling, instructions for use, promotional statements and sales context can all affect how intended use is interpreted.
For that reason, classification work should begin before claims are finalized. A device description that appears low risk from an engineering perspective can become a higher-risk regulatory product if the manufacturer claims direct diagnostic decision support, life-sustaining use, implantable use or use in a vulnerable population.
What each FDA class usually means
| FDA class | General meaning | Typical regulatory impact |
|---|---|---|
| Class I | Lowest risk category | Subject to general controls; many Class I devices are exempt from premarket notification, but exemptions have limits. |
| Class II | Moderate risk category | Subject to general controls and special controls. Many Class II devices require 510(k) clearance unless an exemption applies. |
| Class III | Highest risk category | Generally requires premarket approval, especially where insufficient controls exist to assure safety and effectiveness. |
General controls include baseline requirements such as registration, listing, labeling, records, reporting and quality system obligations unless a specific exemption applies. Special controls for Class II devices may include performance standards, post-market surveillance, patient registries, special labeling or premarket data requirements. For Class III devices, the evidence burden is typically much higher because the device may support or sustain life, prevent impairment of human health, or present a potential unreasonable risk of illness or injury.
If a device is novel and there is no legally marketed predicate, the FDA De Novo pathway may be relevant for certain low- to moderate-risk devices. If a manufacturer needs a formal FDA view on classification or the applicable marketing pathway, a 513(g) request may be considered. These routes should not be treated as interchangeable with a simple database search; they serve different regulatory purposes.
How the EU MDR classifies medical equipment
In the European Union, general medical devices are classified under Regulation (EU) 2017/745, commonly called the Medical Device Regulation or MDR. The MDR uses Class I, Class IIa, Class IIb and Class III. Classification is carried out under Annex VIII, which contains rules based on intended purpose, duration of use, invasiveness, active status, implantability, contact with the body, administration or removal of substances and several special cases.
The EU framework is not a simple translation of the FDA framework. EU Class IIa and Class IIb do not have direct FDA equivalents, and EU Class III is not automatically the same as FDA Class III. The European approach also places strong emphasis on conformity assessment, clinical evaluation, technical documentation and the role of notified bodies.
MDR classes and notified body involvement
Class I devices with no sterile, measuring or reusable surgical instrument aspect may often follow a manufacturer declaration route, provided all applicable MDR obligations are met. However, Class I sterile devices, Class I devices with a measuring function and Class I reusable surgical instruments require notified body involvement for the relevant aspects. Class IIa, Class IIb and Class III devices generally require notified body assessment before CE marking.
The MDR also applies a strict rule when multiple classification rules could apply: the rule resulting in the higher classification prevails. This matters for complex systems. A device may be active, invasive, software-driven and intended for long-term use at the same time. The classification file should therefore show not only which rule was selected, but also which plausible rules were considered and why they were accepted or rejected.
Recent EU guidance to note
The Medical Device Coordination Group published MDCG 2021-24 Rev.1 on classification of medical devices in April 2026. This guidance supports the application of MDR Annex VIII and gives practical explanations for rule interpretation. For in vitro diagnostic medical devices, MDCG 2020-16 Rev.5 on IVDR classification rules was published in September 2026. These guidance documents are not the legal text itself, but they are important reference points for manufacturers, notified bodies and regulators.
IVD classification follows a separate logic
In vitro diagnostic medical devices are handled separately in the EU under Regulation (EU) 2017/746, known as the IVDR. Instead of MDR Classes I, IIa, IIb and III, the IVDR uses Classes A, B, C and D. Class A is the lowest-risk category and Class D is the highest-risk category, particularly where incorrect results may create serious public health consequences, such as screening for high-risk transmissible agents.
The IVDR classification rules focus less on physical contact with the body and more on the consequences of incorrect test results. This is a fundamental difference from many equipment-based assumptions. A diagnostic test may never touch a patient directly, yet still be high risk if a false negative or false positive could delay treatment, affect transfusion compatibility, influence infectious disease control or guide critical therapy.
IMDRF principles also emphasize risk-based IVD classification, taking into account the intended use, the significance of the information provided, and the potential impact on individuals and public health. Manufacturers should therefore avoid classifying IVDs by instrument complexity alone. The clinical decision that depends on the result is often more important than the physical form of the analyzer, reagent or software module.
FDA and EU classification are not interchangeable
A common mistake is to assume that one jurisdiction’s classification can be converted into another’s. Classification can inform regulatory strategy across markets, but it cannot replace jurisdiction-specific analysis. The same device may have different classes, evidence expectations and review routes in different markets. See also: Implants.
| Issue | FDA approach | EU MDR or IVDR approach |
|---|---|---|
| Core class system | Class I, II, III | MDR: Class I, IIa, IIb, III. IVDR: Class A, B, C, D. |
| Main classification driver | Risk and regulatory controls needed for safety and effectiveness | Intended purpose plus Annex VIII rules and highest applicable rule |
| Market pathway | Exemption, 510(k), De Novo, PMA or other pathway depending on device type | Conformity assessment route, CE marking and notified body involvement depending on class |
| Software | Assessed by intended use, claims, risk and applicable FDA software policies | Assessed under MDR or IVDR software rules, including standalone software classification |
| Formal clarification | 513(g) request may support formal classification feedback | Disputes may involve notified bodies and competent authorities under EU procedures |
For multinational planning, the useful question is not “What is the equivalent class?” but “What intended use, risk, evidence and review route does each regulator require?” This framing reduces the risk of underestimating clinical evidence, quality system scope, labeling controls or post-market surveillance duties.
A practical workflow for documenting classification
A defensible classification decision should be documented as part of the regulatory file, not left in an informal spreadsheet. The following workflow can help structure the analysis:
- Define the product and variants. Identify hardware, software, accessories, consumables, sterile versions, reusable parts and optional modules.
- Write the intended purpose before choosing the class. Include target users, patient population, clinical setting, anatomical site, duration of use and diagnostic or therapeutic claims.
- Separate medical device status from classification. First confirm whether the product is a medical device, IVD, accessory, system component, wellness product or another regulated product type.
- Map the applicable rules. For FDA, search generic device types, product codes and classification regulations. For the EU, apply MDR or IVDR Annex VIII rules in a documented sequence.
- Test higher-risk scenarios. Review whether software decision support, implantability, sterility, measuring function, energy delivery, drug-device combination features or vulnerable users change the class.
- Record rejected alternatives. A strong file explains why a higher or lower class was not selected, especially when more than one rule appears relevant.
- Align evidence and labeling. The selected class must match technical documentation, clinical or performance evaluation, risk management, instructions for use and marketing claims.
- Monitor regulatory updates. Classification may need reassessment when guidance changes, claims expand, software is modified, accessories are added or post-market signals reveal new risks.
This workflow is particularly important for connected equipment, software as a medical device, AI-enabled functions, diagnostic platforms and combination systems. In these areas, classification often turns on detailed intended-use wording and the clinical consequence of the output.
Common edge cases that change classification
Software and data-driven equipment
Software can be a medical device in its own right or part of a larger device. A dashboard that only stores administrative data is different from software that analyzes physiological signals, flags clinical deterioration or recommends treatment. Under both FDA and EU frameworks, the manufacturer’s claims and the role of the software in clinical decision-making are key classification factors.
Accessories and systems
Accessories should not be treated as automatically low risk. An accessory may be classified separately or may influence the safety and performance of the main device. Power supplies, sensors, cartridges, calibration materials and reusable instruments can create their own regulatory obligations, especially when failure could affect clinical output.
Sterile, reusable, implantable and invasive features
Sterility, reuse and body contact can substantially affect classification and conformity assessment. A non-sterile general instrument and a sterile reusable surgical instrument may appear similar in a product catalog, but regulators may view them differently because cleaning, disinfection, sterilization validation and user safety introduce additional risks.
Borderline products
Some products sit near the boundary between medical devices, medicines, personal protective equipment, general laboratory equipment or wellness products. Borderline analysis should be based on intended purpose, mode of action and claims. When the main intended action is pharmacological, immunological or metabolic, the product may not be regulated as a medical device even if it is used with equipment or has a device-like form.
Frequently asked questions
Is medical equipment always a medical device?
No. “Medical equipment” is a broad commercial phrase. A product becomes a medical device when it meets the legal definition in the relevant jurisdiction and is intended for a medical purpose. General furniture, facility equipment or administrative software used in healthcare settings may not be medical devices unless medical claims or functions bring them within scope.
Can a Class I device require regulatory work?
Yes. Low class does not mean no obligations. Registration, listing, labeling, quality system controls, technical documentation, post-market surveillance and complaint handling may still apply, depending on the jurisdiction and exemption status.
Does FDA Class II equal EU Class IIa?
No. The names look similar, but the systems are different. FDA Class II means general and special controls are needed under the U.S. framework. EU Class IIa is one of several MDR risk classes determined by Annex VIII rules. A separate analysis is required for each market.
When should classification be revisited?
Classification should be revisited when intended use changes, indications expand, software functions are modified, accessories are added, a sterile or reusable version is introduced, new clinical claims are made, or updated guidance affects interpretation. It should also be reviewed when post-market data suggests a different risk profile.
What is the biggest classification mistake?
The biggest mistake is choosing a class from a product name alone. Regulators look at intended purpose, claims, users, patient population, technology, duration of use and risk. A well-documented classification rationale is often more valuable than a quick label copied from a similar product.